Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Major Histocompatibility Complex class II (MHC II) presenting a tetanus toxoid helper epitope is a fundamental molecular complex required for the activation of the adaptive immune system. This complex consists of an MHC II molecule, such as HLA-DR, which binds and displays immunogenic peptides derived from the tetanus toxin, most notably the ‘universal’ epitopes P2 and P30 (UniProt P04958). These epitopes are characterized by their ability to bind a wide range of MHC II alleles, making them effective across a diverse human population (Panina-Bordignon et al., 1989). When this MHC II-peptide complex is recognized by the T-cell receptor (TCR) on CD4+ helper T cells, it triggers a signaling cascade that leads to T-cell activation, proliferation, and the secretion of cytokines like interleukin-2 and interferon-gamma. This interaction is the primary mechanism of action for tetanus toxoid vaccines and is critically utilized in conjugate vaccines to provide the necessary T-cell help for antibody production against polysaccharide antigens (StatPearls, 2023). Furthermore, this complex is a target in the development of advanced immunotherapies, including peptide-based cancer vaccines designed to recruit helper T cells to enhance anti-tumor immunity. In clinical research, the complex is also used as a diagnostic tool to assess the functional status of the cellular immune system through assays like ELISpot or flow cytometry.
The complex acts as a ligand for the T-cell receptor (TCR) on CD4+ T cells. Recognition of the universal epitopes P2 and P30 presented by MHC II molecules triggers the activation of the TCR-CD3 complex, leading to downstream signaling through the Zap70 and PLC-gamma pathways (Valmori et al., 1992). This results in the activation of transcription factors that drive the production of cytokines and the expansion of helper T-cell populations, which are essential for providing help to B cells for antibody production.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Major Histocompatibility Complex class II-tetanus toxoid peptide complex (MHC II-TT complex) (MHC II-TT complex).